| Year |
Citation |
Score |
| 2024 |
Ye J, Pan H, Reaman G, Roychoudhury S, Lu C, Renfro LA, Ji Y, Liu R, Yuan Y, Zhang W. Considerations on Design and Analysis of External Control in Pediatric Oncology. Medical Research Archives. 12. PMID 39026931 DOI: 10.18103/mra.v12i1.5088 |
0.376 |
|
| 2024 |
Li Y, Nelson R, Izem R, Broglio K, Mundayat R, Gamalo M, Wen Y, Pan H, Sun H, Ye J. Unlocking the Potential: A Systematic Review of Master Protocol in Pediatrics. Therapeutic Innovation & Regulatory Science. PMID 38653950 DOI: 10.1007/s43441-024-00656-z |
0.301 |
|
| 2022 |
Li C, Sun H, Cheng C, Tang L, Pan H. A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs. Contemporary Clinical Trials Communications. 30: 100990. PMID 36203850 DOI: 10.1016/j.conctc.2022.100990 |
0.346 |
|
| 2022 |
Su X, Li Y, Müller P, Hsu CW, Pan H, Do KA. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling. Pharmaceutical Statistics. PMID 35748220 DOI: 10.1002/pst.2249 |
0.411 |
|
| 2022 |
Wu J, Pan H, Hsu CW. Two-stage screened selection designs for randomized phase II trials with time-to-event endpoints. Biometrical Journal. Biometrische Zeitschrift. PMID 35661226 DOI: 10.1002/bimj.202100305 |
0.362 |
|
| 2021 |
Mu R, Hu Z, Xu G, Pan H. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials. Bmc Medical Research Methodology. 21: 278. PMID 34895153 DOI: 10.1186/s12874-021-01455-y |
0.347 |
|
| 2021 |
Mu R, Xu G, Liu G, Pan H. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials. Contemporary Clinical Trials. 106504. PMID 34303862 DOI: 10.1016/j.cct.2021.106504 |
0.412 |
|
| 2021 |
Wu J, Pan H, Hsu CW. Bayesian single-arm phase II trial designs with time-to-event endpoints. Pharmaceutical Statistics. PMID 34085764 DOI: 10.1002/pst.2143 |
0.337 |
|
| 2020 |
Mu R, Pan H, Xu G. A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials. Statistics in Medicine. PMID 33094528 DOI: 10.1002/sim.8780 |
0.322 |
|
| 2020 |
Li C, Pan H. A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries. Plos One. 15: e0237254. PMID 32853204 DOI: 10.1371/Journal.Pone.0237254 |
0.463 |
|
| 2020 |
Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharmaceutical Statistics. PMID 32248647 DOI: 10.1002/Pst.2013 |
0.545 |
|
| 2020 |
Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials. 105972. PMID 32151751 DOI: 10.1016/J.Cct.2020.105972 |
0.516 |
|
| 2020 |
Yan F, Zhang L, Zhou Y, Pan H, Liu S, Yuan Y. BOIN: An R Package for Designing Single-Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs Journal of Statistical Software. 94. DOI: 10.18637/jss.v094.i13 |
0.319 |
|
| 2018 |
Wu K, Pan H, Li C, Zhao Q, Wang L, Xia J. An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment. Plos One. 13: e0208354. PMID 30521581 DOI: 10.1371/Journal.Pone.0208354 |
0.315 |
|
| 2018 |
Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine. PMID 29682777 DOI: 10.1002/Sim.7674 |
0.541 |
|
| 2018 |
Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. Bmc Medical Research Methodology. 18: 32. PMID 29580203 DOI: 10.1186/S12874-018-0473-2 |
0.399 |
|
| 2017 |
Pan H, Yuan Y, Xia J. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. Journal of the Royal Statistical Society. Series C, Applied Statistics. 66: 979-996. PMID 29249839 DOI: 10.1111/Rssc.12204 |
0.474 |
|
| 2017 |
Zhao L, Zhou Y, Pan H, Yin Y, Chai G, Mu Y, Xiao F, Lin SH, Shi M. Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients. Journal of Cancer. 8: 3242-3250. PMID 29158796 DOI: 10.7150/Jca.20835 |
0.327 |
|
| 2016 |
Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials. Statistics in Medicine. PMID 27027650 DOI: 10.1002/Sim.6933 |
0.495 |
|
| 2016 |
Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine. PMID 26991076 DOI: 10.1002/Sim.6941 |
0.506 |
|
| 2015 |
Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine. 34: 1681-94. PMID 25626429 DOI: 10.1002/Sim.6442 |
0.514 |
|
| 2014 |
Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. Plos One. 9: e98147. PMID 24875783 DOI: 10.1371/Journal.Pone.0098147 |
0.448 |
|
| 2014 |
Pan H, Xie F, Liu P, Xia J, Ji Y. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials (London, England). 11: 49-59. PMID 24137041 DOI: 10.1177/1740774513500081 |
0.38 |
|
| 2014 |
Pan H, Li C, Wang L, Jiang Z, Xia J. A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies Communications in Statistics - Simulation and Computation. 43: 254-268. DOI: 10.1080/03610918.2012.700365 |
0.443 |
|
| 2013 |
Pan H, Huang P, Wang Z, Wang L, Li C, Xia J. A novel Bayesian seamless phase I/II design. Plos One. 8: e73060. PMID 24023809 DOI: 10.1371/Journal.Pone.0073060 |
0.45 |
|
| Show low-probability matches. |
